Amylin estimates revised by Merrill Lynch

Amylin Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Thomas McGahren at a neutral rating following second-quarter results, but the EPS estimate for 2005 was widened to a loss of $1.9 per share from a loss of $1.66. Amylin shares Friday declined $0.58, or 2.90%, to close at $19.45 on volume of 3,525,839 shares versus the three-month running average of 3,678,680 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.